Blood dendritic cells in patients with chronic lymphocytic leukaemia.

Abstract : Myeloid and plasmacytoid dendritic cells (MDC, PDC) play a key role in the initiation of immune responses. We found a reduction of both DC subsets in 42 patients with chronic lymphocytic leukaemia (CLL) at diagnosis (P<0.0001 and 0.0001 vs. controls, respectively), likely related to the high secretion of CCL22 and CXCL12 (P=0.04 and 0.008 vs. controls, respectively) by leukaemic cells. However, CD14+ monocytes from CLL patients could give rise to functional IL-12p70-secreting monocyte-derived DCs, capable of inducing a type 1 polarization immunostimulatory profile. These monocyte-derived DCs from CLL patients efficiently migrate in response to CCL19/MIP-3beta chemokine, suggesting that functional autologous DCs can be generated for immunotherapeutic purposes to circumvent DC defects in CLL.
Type de document :
Article dans une revue
Immunobiology, Elsevier, 2008, 213 (6), pp.493-8. 〈10.1016/j.imbio.2007.11.009〉
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-00483520
Contributeur : Philippe Saas <>
Soumis le : vendredi 14 mai 2010 - 13:57:25
Dernière modification le : vendredi 16 février 2018 - 01:18:56

Identifiants

Collections

Citation

Naira Ben Mami, Mohamad Mohty, Thérèse Aurran-Schleinitz, Daniel Olive, Béatrice Gaugler. Blood dendritic cells in patients with chronic lymphocytic leukaemia.. Immunobiology, Elsevier, 2008, 213 (6), pp.493-8. 〈10.1016/j.imbio.2007.11.009〉. 〈inserm-00483520〉

Partager

Métriques

Consultations de la notice

411